healthŌme and GalenusRx Forge Strategic Partnership to Launch Genomics-based Personalized Medication Safety Program
February 3, 2026

GalenusRx Co-Founder and Team Publish in Pharmaceuticals

MONTVERDE, FL – November 25, 2025 – GalenusRx is proud to announce that under the leadership of co-Founder and President, Veronique Michaud, she and team members Matthew Arwood and David Thacker, have published in Pharmaceuticals. The article, entitled Protein Levels of 16 Cytochrome P450s and 2 Carboxyl Esterases Using Absolute Quantitative Proteomics: CYP2C9 and CYP3A4 Are the Most Abundant Isoforms in Human Liver and Intestine, Respectively aimed to characterize the protein expression levels of 16 Cytochrome P450s (CYP450s) and 2 carboxylesterases (CESs) in human liver and intestinal tissues using absolute quantification by HPLC-MS/MS. 

Findings demonstrated that the absolute quantification method used was reliable and produced consistent results across two different in vitro hepatic systems (HHEP and HLM). Importantly, this study provides new, valuable insights to improve in vitro/in vivo extrapolation and more informed predictive pharmacokinetic modeling strategies and supports the utility of absolute quantification approaches for profiling drug-metabolizing enzymes.

Congratulations to Dr. Michaud and her team!

Other Posts

03/05/2026

MONTVERDE, FL – March 5, 2026 – GalenusRx is proud to announce that COO and…

02/03/2026

MONTVERDE, FL – November 25, 2025 – GalenusRx is proud to announce that under the…

11/06/2025

MONTVERDE, FL – November 6, 2025 – GalenusRx is proud to partner with Hesperos Inc.…

11/06/2025

MONTVERDE, FL – November 6, 2025 – On behalf of GalenusRx, we are proud to…

04/23/2025

Fernandina Beach, FL – April 21, 2025 – GalenusRx, a leader in innovative medication safety…